OptimizeRx (NASDAQ: OPRX) switches auditors from UHY LLP to Grant Thornton

robot
Abstract generation in progress

OptimizeRx (NASDAQ: OPRX) has announced a change in its independent auditor, dismissing UHY LLP and appointing Grant Thornton LLP for the fiscal year ending December 31, 2026. UHY’s audit reports for 2024 and 2025 were unqualified, meaning there were no adverse opinions or disagreements, despite a previously disclosed material weakness in internal control over financial reporting related to third-party data. This change appears to be a standard transition as there were no disagreements or reportable events between OptimizeRx and UHY.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin